
  
    
      
        Background_NNP
        The_DT iron_NN status_NN of_IN an_DT individual_NN may_MD play_VB an_DT important_JJ
        role_NN in_IN cardiovascular_JJ health_NN ,_, with_IN either_DT an_DT excess_NN of_IN
        iron_NN (_( mainly_RB the_DT storage_NN form_NN ferritin_NN )_) or_CC iron_NN deficiency_NN
        leading_VBG to_TO significant_JJ problems_NNS ._. Sullivan_NNP [_NN 1_CD ]_NN has_VBZ
        proposed_VBN that_IN excess_JJ iron_NN (_( i_NNP ._. e_SYM ._. ,_, any_DT iron_NN in_IN the_DT ferritin_NN
        form_NN )_) leads_VBZ to_TO formation_NN of_IN free_JJ radicals_NNS that_WDT can_MD worsen_VB
        ischemic_JJ myocardial_NN injury_NN and_CC contribute_VB to_TO atherogenesis_NNS ._.
        This_DT hypothesis_NNS has_VBZ considerable_JJ experimental_JJ [_NN 2_CD 3_CD ]_NN and_CC
        epidemiological_JJ [_NN 4_CD 5_CD ]_NN support_NN ._. However_RB ,_, the_DT "_'' iron_NN
        hypothesis_NNS "_'' has_VBZ not_RB been_VBN universally_RB accepted_VBN [_NN 6_CD ]_NN ,_, and_CC
        considerable_JJ debate_NN on_IN the_DT role_NN of_IN iron_NN overload_NN on_IN
        cardiovascular_JJ disease_NN continues_VBZ [_NN 7_CD 8_CD 9_CD 10_CD ]_NN ._.
        Iron_NNP deficiency_NN has_VBZ also_RB been_VBN shown_VBN to_TO lead_VB to_TO
        ventricular_NN hypertrophy_NN in_IN developing_VBG rats_NNS [_NN 11_CD 12_CD 13_CD 14_CD 15_CD
        16_CD 17_CD ]_NN ._. While_IN the_DT mechanisms_NNS responsible_JJ for_IN this_DT
        hypertrophy_NN have_VBP received_VBN little_JJ research_NN attention_NN ,_,
        studies_NNS have_VBP documented_VBN an_DT eccentric_JJ hypertrophic_JJ pattern_NN [_NN
        15_CD 16_CD 17_CD ]_NN which_WDT has_VBZ led_VBN investigators_NNS to_TO suspect_VB a_DT
        ventricular_NN volume_NN overload_NN at_IN end_NN diastole_NN as_IN a_DT primary_JJ
        hypertrophic_JJ stimulus_NN ._. The_DT hypothesized_VBN volume_NN load_NN ,_, if_IN it_PRP
        occurs_VBZ ,_, does_VBZ not_RB result_VB from_IN a_DT change_NN in_IN blood_NN volume_NN [_NN 18_CD
        ]_NN ._. It_PRP has_VBZ also_RB been_VBN hypothesized_VBN that_IN a_DT chronic_JJ elevation_NN
        in_IN sympathetic_JJ nervous_JJ system_NN activity_NN is_VBZ involved_VBN in_IN iron_NN
        deficiency-induced_JJ hypertrophy_NN ._. Evidence_NN to_TO support_VB this_DT
        view_NN includes_VBZ the_DT observations_NNS of_IN increased_VBN levels_NNS of_IN
        norepinephrine_NN in_IN plasma_NN and_CC urine_NN ,_, and_CC decreased_VBD
        norepinephrine_NN content_NN in_IN the_DT iron_NN deficient_NN heart_NN [_NN 19_CD 20_CD
        21_CD 22_CD ]_NN ._. Rossi_NNP [_NN 23_CD ]_NN ,_, after_IN finding_VBG that_DT reserpine_NN
        administration_NN prevented_VBD the_DT development_NN of_IN this_DT
        hypertrophy_NN ,_, even_RB suggested_VBD that_DT norepinephrine_NN is_VBZ the_DT
        causal_NN agent_NN in_IN the_DT pathology_NN ._. While_IN little_RB published_VBN
        research_NN has_VBZ subsequently_RB focused_VBN on_IN iron_NN deficiency_NN
        hypertrophy_NN ,_, there_EX have_VBP been_VBN numerous_JJ studies_NNS investigating_VBG
        the_DT role_NN of_IN sympathetic_JJ neurotransmission_NN with_IN cardiac_JJ
        hypertrophy_NN induced_VBN via_IN various_JJ methods_NNS (_( coronary_JJ artery_NN
        ligation_NN ,_, chronic_JJ pressure_NN overload_NN ,_, transgenic_JJ models_NNS ,_,
        etc_FW ._. )_) ._. Most_JJS have_VBP demonstrated_VBN alterations_NNS in_IN either_DT plasma_NN
        or_CC heart_NN norepinephrine_NN content_NN ,_, and_CC a_DT de-sensitization_JJ of_IN
        the_DT beta-adrenergic_JJ receptors_NNS of_IN the_DT heart_NN [_NN 24_CD 25_CD 26_CD 27_CD 28_CD
        29_CD 30_CD 31_CD 32_CD 33_CD ]_NN ._. Recently_RB ,_, the_DT alpha-adrenergic_JJ receptor_NN
        has_VBZ been_VBN shown_VBN in_IN vitro_NN to_TO be_VB an_DT important_JJ modulator_NN of_IN
        ventricular_NN hypertrophy_NN ._. However_RB ,_, even_RB in_IN transgenic_JJ animal_NN
        models_NNS overexpressing_VBG alpha_NN receptors_NNS ,_, the_DT beta-adrenergic_JJ
        receptor_NN appears_VBZ to_TO play_VB an_DT important_JJ role_NN in_IN hypertrophy_NN
        development_NN and_CC the_DT transition_NN to_TO heart_NN failure_NN [_NN 34_CD 35_CD ]_NN ._.
        Regardless_RB of_IN which_WDT receptors_NNS are_VBP involved_VBN in_IN the_DT various_JJ
        forms_NNS of_IN hypertrophy_NN ,_, the_DT sympathetic_JJ nervous_JJ system_NN does_VBZ
        appear_VB to_TO play_VB a_DT role_NN in_IN most_JJS ,_, if_IN not_RB all_DT ,_, forms_NNS of_IN cardiac_JJ
        hypertrophy_NN ,_, and_CC much_JJ remains_VBZ to_TO be_VB done_VBN in_IN this_DT area_NN [_NN 36_CD
        ]_NN ._.
        Almost_RB no_DT attention_NN has_VBZ been_VBN paid_VBN to_TO the_DT peripheral_JJ
        vascular_NN consequences_NNS of_IN iron_NN deficiency_NN [_NN 37_CD ]_NN ._. With_IN iron_NN
        deficiency_NN ,_, the_DT poor_JJ oxygen-carrying_JJ capacity_NN of_IN the_DT blood_NN
        must_MD be_VB offset_VBN in_IN order_NN for_IN the_DT animal_NN to_TO develop_VB to_TO full_JJ
        maturity_NN ._. Therefore_RB ,_, the_DT chronic_JJ sympathetic_JJ activation_NN
        associated_VBN with_IN iron_NN deficiency_NN should_MD result_VB in_IN increased_VBN
        cardiac_JJ output_NN ._. In_IN turn_NN ,_, flow_NN through_IN the_DT major_JJ arterial_NN
        network_NN would_MD be_VB enhanced_VBN in_IN an_DT attempt_NN to_TO maintain_VB near_IN
        normal_JJ oxygen_NN delivery_NN ._. Kamiya_NNP and_CC Togawa_NNP [_NN 38_CD ]_NN have_VBP found_VBN
        that_WDT increased_VBD flow_NN stimulates_NNS remodeling_NN of_IN an_DT artery_NN to_TO a_DT
        larger_JJR diameter_NN through_IN an_DT endothelial_NN dependent_JJ mechanism_NN ._.
        It_PRP has_VBZ yet_RB to_TO be_VB demonstrated_VBN whether_IN iron_NN deficiency_NN will_MD
        stimulate_VB a_DT similar_JJ arterial_NN remodeling_NN ._.
        Collagen_NNP is_VBZ an_DT integral_JJ component_NN of_IN the_DT arterial_NN wall_NN ,_,
        providing_VBG rigidity_NN and_CC support_NN ._. Iron_NNP is_VBZ necessary_JJ in_IN the_DT
        synthesis_NN of_IN collagen_NN [_NN 39_CD ]_NN ,_, and_CC collagen_NN content_NN has_VBZ
        been_VBN shown_VBN to_TO be_VB reduced_VBN in_IN iron_NN deficient_NN hearts_NNS [_NN 40_CD ]_NN ._.
        If_IN this_DT is_VBZ similarly_RB true_JJ for_IN arteries_NNS in_IN iron_NN deficient_NN
        animals_NNS ,_, a_DT significant_JJ increase_NN in_IN distensibility_NN would_MD
        result_VB ,_, altering_VBG the_DT normal_JJ pressure-volume_JJ
        relationship_NN ._.
        We_PRP investigated_VBD three_CD hypotheses_NNS using_VBG anesthetized_JJ
        rats_NNS ._. First_LS ,_, we_PRP hypothesized_VBN that_IN in_IN iron_NN deficient_NN rats_NNS ,_,
        intravenous_JJ norepinephrine_NN would_MD cause_VB an_DT altered_VBN
        cardiovascular_JJ response_NN ,_, either_CC in_IN heart_NN rate_NN or_CC rate_NN of_IN
        arterial_NN pressure_NN generation_NN (_( contractility_NN ,_, dp_NN •_NN dt_NN -_: 1_LS )_) ._.
        Second_JJ ,_, we_PRP hypothesized_VBN that_DT iron_NN deficient_NN arteries_NNS would_MD
        be_VB larger_JJR and_CC more_RBR distensible_JJ than_IN in_IN iron_NN replete_JJ
        controls_NNS ._. Finally_RB ,_, we_PRP hypothesized_VBN that_IN a_DT daily_JJ injection_NN
        of_IN the_DT beta-adrenergic_JJ antagonist_NN propanolol_NN would_MD
        significantly_RB reduce_VB the_DT development_NN of_IN ventricular_NN
        hypertrophy_NN ._.
        Our_PRP$ results_NNS suggest_VBP that_DT iron_NN deficient_NN ,_, hypertrophic_JJ
        hearts_NNS display_VBP a_DT hyper-sensitive_JJ inotropic_JJ ,_, but_CC not_RB
        chronotropic_JJ ,_, response_NN to_TO norepinephrine_NN ._. Second_JJ ,_, abdominal_NN
        aortas_NNS from_IN iron_NN deficient_NN rats_NNS display_VBP not_RB only_RB increased_VBN
        diameters_NNS ,_, but_CC also_RB significant_JJ increases_NNS in_IN
        distensibility_NN ._. Finally_RB ,_, propanolol_NN injections_NNS do_VBP not_RB
        prevent_VB the_DT development_NN of_IN iron_NN deficient_NN cardiac_JJ
        hypertrophy_NN ,_, drawing_VBG into_IN question_NN the_DT potential_JJ causal_NN
        relationship_NN between_IN beta-adrenergic_JJ neurotransmission_NN and_CC
        this_DT form_NN of_IN hypertrophy_NN ._.
      
      
        Results_NNS and_CC Discussion_NNP
        
          Body_NN weight_NN ,_, heart_NN weight_NN ,_, and_CC hematocrit_NN
          (_( Experiments_NNS 1_CD and_CC 2_LS )_)
          Rat_NNP growth_NN rate_NN is_VBZ shown_VBN in_IN figure_NN 1_CD ._. There_EX were_VBD no_DT
          differences_NNS between_IN any_DT of_IN the_DT experimental_JJ groups_NNS (_( see_VB
          Materials_NNPS and_CC Methods_NNP )_) until_IN the_DT animals_NNS reached_VBD 45_CD days_NNS
          of_IN age_NN ,_, after_IN which_WDT ,_, iron_NN deficient_NN rats_NNS are_VBP of_IN less_JJR mass_NN
          than_IN controls_NNS (_( *_NN ,_, p_NN <_NN 0_CD ._. 05_CD )_) ._. Figure_NN 1_CD also_RB shows_VBZ the_DT
          final_JJ mean_NN body_NN mass_NN of_IN the_DT four_CD experimental_JJ groups_NNS ._.
          Iron_NNP deficient_NN and_CC control_NN groups_NNS more_RBR than_IN doubled_VBD their_PRP$
          body_NN mass_NN from_IN 1_CD week_NN to_TO 1_CD month_NN on_IN the_DT respective_JJ diets_NNS
          (_( †_NN ,_, p_NN <_NN 0_CD ._. 0001_CD )_) ._. The_DT control_NN rats_NNS also_RB had_VBD a_DT
          significantly_RB greater_JJR mass_NN than_IN the_DT iron_NN deficient_NN rats_NNS
          (_( p_NN =_SYM 0_CD ._. 0004_CD )_) in_IN the_DT one_CD month_NN group_NN (_( *_NN ,_, p_NN =_SYM 0_CD ._. 0006_CD )_) ,_, but_CC
          not_RB at_IN one_CD week_NN (_( p_NN =_SYM 0_CD ._. 1530_CD )_) ._. The_DT control_NN rats_NNS in_IN this_DT
          study_NN increased_VBN mass_NN at_IN a_DT rate_NN similar_JJ to_TO that_DT published_VBD
          for_IN the_DT ad_NN libitum_NN fed_VBD CD_NNP rat_NN [_NN 41_CD 42_CD ]_NN ,_, suggesting_VBG
          growth_NN was_VBD inhibited_VBD by_IN iron_NN deficiency_NN ._. It_PRP is_VBZ likely_JJ
          that_DT growth_NN inhibition_NN is_VBZ attributable_JJ to_TO metabolic_JJ
          causes_NNS arising_VBG from_IN both_DT oxygen_NN delivery_NN and_CC
          mitochondrial_NN insufficiencies_NNS associated_VBN with_IN iron_NN
          deficiency_NN [_NN 14_CD ]_NN ._. The_DT growth_NN data_NN for_IN both_DT the_DT control_NN
          and_CC iron_NN deficient_NN groups_NNS are_VBP also_RB similar_JJ to_TO that_DT
          reported_VBD for_IN male_JJ Wistar_NNP rats_NNS fed_VBD an_DT iron_NN and_CC copper_NN
          deficient_NN diet_NN [_NN 15_CD ]_NN ,_, but_CC the_DT iron_NN deficient_NN rats_NNS at_IN 52_CD
          days_NNS of_IN age_NN were_VBD larger_JJR than_IN reports_NNS of_IN 10_CD week_NN old_JJ
          Harlan_NNP Sprague-_NNP Dawley_NNP rats_NNS fed_VBD an_DT AIN-_NNP 76_CD iron_NN deficient_NN
          diet_NN [_NN 17_CD ]_NN ._.
          Heart_NNP mass_NN increased_VBN significantly_RB from_IN 1_CD week_NN to_TO 1_CD
          month_NN of_IN the_DT diets_NNS (_( figure_NN 2_CD ,_, †_NN ,_, p_NN <_NN 0_CD ._. 0001_CD )_) ._. Diet_NNP
          group_NN differences_NNS were_VBD not_RB apparent_JJ at_IN 1_CD week_NN (_( p_NN =_SYM
          0_CD ._. 8674_CD )_) ,_, but_CC the_DT hearts_NNS of_IN iron_NN deficient_NN rats_NNS were_VBD of_IN
          greater_JJR mass_NN at_IN 1_CD month_NN (_( *_NN ,_, p_NN =_SYM 0_CD ._. 0357_CD )_) ,_, indicating_VBG that_IN
          the_DT heart_NN has_VBZ undergone_VBN hypertrophy_NN by_IN this_DT time_NN ._. These_DT
          differences_NNS remained_VBD significant_JJ after_IN normalization_NN of_IN
          heart_NN weight_NN to_TO body_NN weight_NN (_( data_NNS not_RB shown_VBN )_) ._. This_DT time_NN
          frame_NN for_IN development_NN of_IN hypertrophy_NN is_VBZ similar_JJ to_TO
          previous_JJ findings_NNS with_IN iron_NN or_CC copper_NN deficiency_NN [_NN 14_CD 15_CD
          16_CD 17_CD 40_CD 43_CD ]_NN ._.
          Mean_VB hematocrit_NN levels_NNS (_( figure_NN 2_CD bottom_NN )_) of_IN iron_NN
          deficient_NN animals_NNS were_VBD significantly_RB less_JJR than_IN controls_NNS
          after_IN 1_CD month_NN (_( *_NN ,_, p_NN <_NN 0_CD ._. 0001_CD )_) ,_, but_CC not_RB 1_CD week_NN (_( p_NN =_SYM
          0_CD ._. 3102_CD )_) ,_, of_IN the_DT respective_JJ diets_NNS ._. Many_JJ studies_NNS have_VBP
          documented_VBN significant_JJ hematocrit_NN decreases_NNS after_IN one_CD
          month_NN of_IN an_DT iron_NN deficient_NN diet_NN [_NN 14_CD 15_CD 16_CD 17_CD 40_CD 43_CD ]_NN ._.
          However_RB ,_, few_JJ of_IN these_DT report_NN data_NN for_IN 1_CD week_NN ,_, though_IN one_CD
          published_VBN study_NN indicated_VBD a_DT small_JJ but_CC significant_JJ
          difference_NN [_NN 15_CD ]_NN ,_, and_CC we_PRP have_VBP observed_VBN a_DT group_NN
          difference_NN after_IN 1_CD week_NN of_IN iron_NN deficiency_NN in_IN another_DT
          study_NN (_( Mullendore_NNP ,_, et_CC ._. al_NN ._. ,_, manuscript_NN in_IN progress_NN )_) ._. We_PRP
          speculate_VBP that_IN the_DT ability_NN to_TO create_VB significant_JJ iron_NN
          deficiency_NN in_IN this_DT short_JJ time_NN is_VBZ dependent_JJ upon_IN the_DT
          purity_NN of_IN the_DT iron_NN deficient_NN diet_NN as_RB well_RB as_IN individual_JJ
          animal_NN differences_NNS ._. Nonetheless_RB ,_, examination_NN of_IN several_JJ
          time_NN points_NNS during_IN the_DT progression_NN of_IN iron_NN deficiency_NN can_MD
          potentially_RB provide_VB important_JJ insights_NNS into_IN the_DT
          development_NN of_IN resulting_VBG physiological_JJ alterations_NNS ._.
        
        
          Experiment_NNP 1_CD :_: Cardiodynamics_NNP
          In_IN these_DT experiments_NNS ,_, an_DT infusion_NN of_IN intravenous_JJ
          saline_NN was_VBD used_VBN to_TO ensure_VB that_IN the_DT delivery_NN method_NN
          employed_VBN did_VBD not_RB evoke_VBP a_DT cardiovascular_JJ response_NN ._. In_IN all_DT
          variables_NNS measured_VBN ,_, which_WDT include_VBP heart_NN rate_NN and_CC
          ventricular_NN contractility_NN (_( figure_NN 3_LS )_) ,_, systolic_JJ and_CC
          diastolic_JJ pressures_NNS (_( figure_NN 4_LS )_) ,_, there_EX were_VBD no_DT differences_NNS
          between_IN pre-infusion_JJ and_CC peak_NN responses_NNS to_TO saline_NN ._.
          Therefore_RB ,_, any_DT differences_NNS seen_VBN with_IN intravenous_JJ
          norepinephrine_NN were_VBD attributable_JJ to_TO the_DT catecholamine_NN and_CC
          not_RB the_DT infusion_NN per_IN sé_NN ._. Prior_RB to_TO the_DT infusion_NN of_IN saline_NN ,_,
          group_NN differences_NNS were_VBD already_RB apparent_JJ between_IN iron_NN
          deficient_NN and_CC control_NN rats_NNS at_IN 1_CD month_NN in_IN heart_NN rate_NN (_( *_NN ,_, p_NN
          =_SYM 0_CD ._. 0025_CD )_) ,_, systolic_JJ (_( *_NN ,_, p_NN =_SYM 0_CD ._. 0041_CD )_) and_CC diastolic_JJ
          pressure_NN (_( *_NN ,_, p_NN =_SYM 0_CD ._. 0020_CD )_) ,_, but_CC not_RB contractility_NN (_( p_NN =_SYM
          0_CD ._. 6373_CD )_) ._. We_PRP believe_VBP these_DT pressure_NN changes_NNS are_VBP associated_VBN
          with_IN vascular_NN remodeling_NN ,_, as_IN discussed_VBN below_IN ._.
          Figure_NN 3_CD also_RB shows_VBZ heart_NN rate_NN and_CC contractility_NN
          immediately_RB prior_RB to_TO ,_, and_CC at_IN peak_NN response_NN to_TO ,_,
          intravenous_JJ norepinephrine_NN infusions_NNS ._. Prior_RB to_TO
          norepinephrine_NN infusion_NN ,_, there_EX were_VBD no_DT differences_NNS
          between_IN iron_NN deficient_NN and_CC control_NN groups_NNS within_IN each_DT
          duration_NN in_IN either_DT heart_NN rate_NN or_CC contractility_NN (_( p_NN >_NN
          0_CD ._. 05_CD )_) ._. Heart_NNP rate_NN was_VBD unchanged_JJ from_IN pre-norepinephrine_JJ
          infusion_NN to_TO peak_VB response_NN (_( p_NN =_SYM 0_CD ._. 3905_CD )_) ._. The_DT only_JJ
          difference_NN in_IN peak_NN heart_NN rate_NN response_NN to_TO norepinephrine_NN
          was_VBD the_DT iron_NN deficient_NN group_NN at_IN 1_CD month_NN (_( #_# ,_, p_NN =_SYM 0_CD ._. 0272_CD )_) ,_,
          which_WDT showed_VBD a_DT significant_JJ decrease_NN ._. Contractility_NNP was_VBD
          significantly_RB increased_VBN for_IN both_DT control_NN (_( #_# ,_, p_NN =_SYM 0_CD ._. 0259_CD )_)
          and_CC iron_NN deficient_NN (_( #_# ,_, p_NN =_SYM 0_CD ._. 0008_CD )_) groups_NNS from_IN
          pre-infusion_JJ to_TO peak_VB response_NN ._. At_IN one_CD month_NN ,_,
          contractility_NN for_IN iron_NN deficient_NN rats_NNS increased_VBD 43_CD ._. 71_CD %_NN
          upon_IN norepinephrine_NN infusion_NN ,_, while_IN the_DT control_NN group_NN at_IN
          1_CD month_NN increased_VBD only_RB 10_CD ._. 0_CD %_NN ._.
          Figure_NN 3_CD demonstrates_VBZ a_DT unique_JJ response_NN pattern_NN to_TO the_DT
          sympathetic_JJ nervous_JJ system_NN neurotransmitter_NN ,_,
          norepinephrine_NN ._. For_IN both_DT control_NN and_CC iron_NN deficient_NN
          groups_NNS ,_, the_DT response_NN to_TO norepinephrine_NN is_VBZ to_TO increase_VB
          contractility_NN in_IN the_DT absence_NN of_IN chronotropic_JJ increases_NNS ._.
          Cardiac_NNP output_NN ,_, therefore_RB ,_, would_MD be_VB expected_VBN to_TO increase_VB
          due_JJ to_TO enhanced_JJ stroke_NN volume_NN ,_, with_IN an_DT uncompromised_JJ
          filling_NN time_NN and_CC a_DT more_RBR powerful_JJ ventricular_NN contraction_NN ._.
          In_IN fact_NN ,_, this_DT pattern_NN is_VBZ even_RB more_RBR exaggerated_JJ in_IN the_DT
          iron_NN deficient_NN animals_NNS at_IN 1_CD month_NN ._. Heart_NNP rate_NN in_IN this_DT
          group_NN was_VBD decreased_VBN ,_, which_WDT allows_VBZ the_DT animal_NN two_CD
          potential_JJ advantages_NNS ._. First_LS ,_, ventricular_NN filling_VBG time_NN
          would_MD be_VB increased_VBN ,_, potentially_RB allowing_VBG for_IN greater_JJR end_NN
          diastolic_JJ and_CC stroke_NN volumes_NNS ._. This_DT would_MD be_VB expected_VBN
          chronically_RB to_TO result_VB in_IN a_DT eccentric_JJ hypertrophic_JJ
          pattern_NN ,_, a_DT condition_NN that_IN we_PRP and_CC others_NNS [_NN 15_CD 17_CD ]_NN have_VBP
          found_VBN in_IN iron_NN deficient_NN rat_NN hearts_NNS ._. Second_JJ ,_, the_DT decrease_NN
          in_IN heart_NN rate_NN in_IN iron_NN deficient_NN hearts_NNS when_WRB
          norepinephrine_NN was_VBD infused_VBN would_MD allow_VB for_IN longer_JJR
          myocardial_NN perfusion_NN time_NN ,_, which_WDT would_MD compensate_VB for_IN the_DT
          decreased_VBN oxygen_NN carrying_VBG capacity_NN of_IN the_DT blood_NN and_CC
          impaired_VBN mitochondrial_NN function_NN [_NN 14_CD ]_NN ._. The_DT iron_NN
          deficient_NN norepinephrine_NN response_NN compliments_NNS the_DT finding_NN
          of_IN an_DT increase_NN in_IN capillary_JJ lumenal_NN volume_NN in_IN iron_NN
          deficient_NN hearts_NNS [_NN 15_CD ]_NN ,_, which_WDT should_MD also_RB allow_VB for_IN
          better_JJR myocardial_NN perfusion_NN during_IN diastole_NN ._.
          Norepinephrine_NNP infusion_NN resulted_VBD in_IN a_DT dramatic_JJ
          enhancement_NN of_IN contractility_NN (_( 43_CD ._. 71_CD %_NN )_) in_IN 1_CD month_NN iron_NN
          deficient_NN rats_NNS when_WRB compared_VBN to_TO 1_CD month_NN control_NN rats_NNS
          (_( 10_CD ._. 0_CD %_NN )_) ._. By_IN utilizing_VBG a_DT hyper-sensitive_JJ response_NN to_TO
          sympathetic_JJ stimulation_NN ,_, coupled_VBN with_IN an_DT unchanged_JJ or_CC
          lower_JJR heart_NN rate_NN ,_, the_DT iron_NN deficient_NN heart_NN can_MD
          potentially_RB offset_VB some_DT of_IN the_DT oxygen_NN delivery_NN
          deficiencies_NNS of_IN anemic_JJ blood_NN without_IN risking_VBG myocardial_NN
          ischemia_NN ._. These_DT appear_VB to_TO be_VB positive_JJ adaptations_NNS ,_, at_IN
          least_JJS short_JJ term_NN ,_, in_IN response_NN to_TO a_DT serious_JJ nutritional_JJ
          challenge_NN ._. Iron_NNP deficient_NN cardiac_JJ hypertrophy_NN is_VBZ not_RB
          unique_JJ in_IN this_DT regard_NN ,_, as_IN Lin_NNP has_VBZ recently_RB documented_VBN
          enhanced_JJ contractility_NN without_IN increased_VBN heart_NN rate_NN in_IN
          hyper-sympathetic_JJ transgenic_JJ mice_NNS [_NN 34_CD ]_NN ._. In_IN contrast_NN ,_,
          there_EX is_VBZ a_DT large_JJ body_NN of_IN evidence_NN which_WDT suggests_VBZ that_IN
          cardiac_JJ hypertrophy_NN which_WDT has_VBZ progressed_VBN to_TO the_DT point_NN of_IN
          pathology_NN ,_, ultimately_RB results_VBZ in_IN a_DT decrease_NN in_IN
          contractility_NN [_NN 25_CD 26_CD 27_CD 29_CD 30_CD 32_CD 33_CD 44_CD 45_CD ]_NN ._. We_PRP have_VBP
          not_RB yet_RB investigated_VBN whether_IN the_DT iron_NN deficient_NN heart_NN
          will_MD similarly_RB lose_VB the_DT augmented_JJ contractility_NN response_NN
          in_IN time_NN ._.
          It_PRP has_VBZ been_VBN suggested_VBN in_IN several_JJ papers_NNS that_IN changes_NNS
          in_IN sympathetic_JJ nervous_JJ system_NN responsiveness_NNS may_MD begin_VB as_IN
          a_DT positive_JJ adaptation_NN ,_, but_CC ultimately_RB results_VBZ in_IN
          pathologic_JJ failure_NN of_IN the_DT myocardium_NN ._. For_IN example_NN ,_,
          Engelhardt_NNP [_NN 46_CD ]_NN ,_, in_IN a_DT study_NN of_IN mice_NNS genetically_RB bred_VBN
          with_IN an_DT increase_NN in_IN beta-adrenergic_JJ receptor_NN density_NN ,_,
          showed_VBD that_WDT increased_VBD contractility_NN was_VBD an_DT initial_JJ
          response_NN ,_, but_CC by_IN 35_CD weeks_NNS contractility_NN was_VBD reduced_VBN by_IN
          50_CD %_NN and_CC ejection_NN fraction_NN by_IN 20_CD %_NN ._. The_DT genetically_RB
          altered_VBN ,_, hyper-adrenergic_JJ heart_NN ultimately_RB failed_VBD after_IN
          initial_JJ enhancement_NN of_IN cardiac_JJ function_NN ._.
          Mukherjee_NNP and_CC Spinale_NNP [_NN 47_CD ]_NN ,_, in_IN a_DT recent_JJ review_NN ,_,
          concluded_VBD that_IN with_IN hypertrophy_NN comes_VBZ a_DT decrease_NN in_IN
          cardiac_JJ contractility_NN as_IN a_DT result_NN of_IN changes_NNS to_TO the_DT
          L-_NNP type_NN Ca_MD 2_CD +_NN channel_NN ._. However_RB ,_, the_DT authors_NNS noted_VBD that_IN this_DT
          adaptation_NN ,_, while_IN generally_RB present_JJ in_IN a_DT failing_VBG
          hypertrophied_JJ myocardium_NN ,_, is_VBZ not_RB necessarily_RB present_JJ in_IN
          less_RBR serious_JJ cardiac_JJ hypertrophies_NNS ._. Similarly_RB ,_, Tse_NNP [_NN 48_CD ]_NN
          found_VBD that_IN in_IN compensated_VBN hypertrophy_NN the_DT population_NN of_IN
          beta-adrenergic_JJ receptors_NNS is_VBZ relatively_RB normal_JJ ,_, but_CC in_IN
          heart_NN failure_NN ,_, the_DT beta_NN receptors_NNS have_VBP both_DT
          down-regulated_JJ and_CC de-sensitized_JJ ._. Sheridan_NNP [_NN 49_CD ]_NN and_CC
          Iaccarino_NNP [_NN 35_CD ]_NN came_VBD to_TO a_DT similar_JJ conclusion_NN regarding_VBG
          heart_NN failure_NN and_CC adrenergic_JJ down-regulation_JJ ._.
          Figures_NNS 4_CD shows_VBZ systolic_JJ and_CC diastolic_JJ pressures_NNS before_IN
          and_CC after_IN the_DT norepinephrine_NN infusion_NN ._. There_EX was_VBD a_DT
          significant_JJ increase_NN in_IN systolic_JJ pressure_NN for_IN both_DT the_DT
          control_NN (_( *_NN ,_, p_NN =_SYM 0_CD ._. 0020_CD )_) and_CC the_DT iron_NN deficient_NN (_( *_NN ,_, p_NN =_SYM
          0_CD ._. 0001_CD )_) groups_NNS from_IN pre-infusion_JJ to_TO peak_VB response_NN ._.
          Diastolic_NNP pressure_NN similarly_RB increased_VBD from_IN pre-infusion_JJ
          to_TO peak_VB response_NN for_IN both_DT control_NN (_( #_# ,_, p_NN =_SYM 0_CD ._. 0040_CD )_) and_CC
          iron_NN deficient_NN (_( #_# ,_, p_NN <_NN 0_CD ._. 0001_CD )_) groups_NNS when_WRB
          norepinephrine_NN was_VBD infused_VBN ._. These_DT observations_NNS are_VBP
          consistent_JJ with_IN the_DT vasoconstrictive_JJ effect_NN of_IN
          norepinephrine_NN ._. Also_RB ,_, increased_VBN heart_NN contractility_NN is_VBZ
          expected_VBN to_TO increase_VB peak_NN systolic_JJ pressure_NN ._. The_DT
          diastolic_JJ pressure_NN of_IN iron_NN deficient_NN rats_NNS was_VBD
          significantly_RB lower_JJR than_IN controls_NNS both_DT before_IN (_( *_NN ,_, p_NN =_SYM
          0_CD ._. 0131_CD )_) and_CC after_IN (_( *_NN ,_, p_NN =_SYM 0_CD ._. 0004_CD )_) norepinephrine_NN
          infusion_NN ._. This_DT is_VBZ consistent_JJ with_IN the_DT idea_NN of_IN vascular_NN
          remodeling_VBG to_TO a_DT larger_JJR arterial_NN diameter_NN with_IN iron_NN
          deficiency_NN (_( discussed_VBN below_IN )_) ,_, which_WDT could_MD reduce_VB the_DT
          afterload_NN against_IN which_WDT the_DT heart_NN must_MD work_VB to_TO eject_NN
          blood_NN ._.
        
        
          Experiment_NNP 2_CD
          Representative_NNP aortas_NNS from_IN control_NN and_CC iron_NN deficient_NN
          rats_NNS after_IN one_CD month_NN on_IN the_DT respective_JJ diets_NNS are_VBP shown_VBN in_IN
          figure_NN 5_CD ,_, and_CC mean_VB aorta_NN external_JJ diameter_NN at_IN 100_CD mmHg_NN
          pressure_NN is_VBZ illustrated_VBN in_IN figure_NN 6_CD ._. There_EX was_VBD a_DT
          significant_JJ duration_NN effect_NN (_( †_NN ,_, p_NN <_NN 0_CD ._. 0001_CD )_) ,_, likely_JJ
          due_NN to_TO body_NN growth_NN ._. Overall_RB ,_, the_DT diameter_NN of_IN aortas_NNS from_IN
          iron_NN deficient_NN rats_NNS was_VBD greater_JJR than_IN from_IN control_NN rats_NNS
          (_( *_NN ,_, p_NN =_SYM 0_CD ._. 0280_CD )_) ._. The_DT regulation_NN of_IN lumenal_NN diameter_NN in_IN
          large_JJ arteries_NNS is_VBZ accomplished_VBN through_IN the_DT maintenance_NN of_IN
          shear_NN stress_NN along_IN the_DT arterial_NN wall_NN [_NN 38_CD 50_CD 51_CD 52_CD 53_CD 54_CD
          ]_NN ._. As_IN blood_NN flow_NN through_IN an_DT artery_NN increases_NNS ,_, shear_NN is_VBZ
          also_RB increased_VBN ,_, and_CC the_DT endothelium_NN releases_NNS nitric_JJ oxide_NN
          for_IN vasodilation_NN [_NN 55_CD ]_NN ._. Chronically_NNP ,_, the_DT arterial_NN wall_NN
          will_MD remodel_NN to_TO a_DT larger_JJR diameter_NN to_TO accommodate_VB the_DT
          increased_VBN flow_NN [_NN 38_CD ]_NN ._. While_IN we_PRP did_VBD not_RB measure_VB arterial_NN
          flow_NN through_IN these_DT iron_NN deficient_NN arteries_NNS ,_, the_DT enhanced_VBN
          inotropic_JJ compensation_NN to_TO iron_VB deficiency_NN ,_, combined_VBN with_IN
          the_DT enlarged_JJ aortic_JJ diameter_NN ,_, leads_VBZ us_PRP to_TO suspect_VB a_DT flow_NN
          dependent_JJ mechanism_NN for_IN remodeling_VBG ._. Future_JJ investigations_NNS
          will_MD be_VB necessary_JJ to_TO confirm_VB this_DT assertion_NN ._.
          Aortic_NNP distensibility_NN ,_, the_DT increase_NN in_IN external_JJ
          diameter_NN during_IN stepwise_NN internal_JJ pressure_NN increases_NNS ,_, is_VBZ
          also_RB shown_VBN in_IN figure_NN 6_CD ._. There_EX is_VBZ a_DT significant_JJ group_NN
          difference_NN (_( *_NN ,_, p_NN =_SYM 0_CD ._. 0101_CD )_) with_IN the_DT iron_NN deficient_NN aortas_NNS
          more_JJR compliant_NN than_IN the_DT controls_NNS overall_JJ ._. A_DT decrease_NN in_IN
          collagen_NN production_NN with_IN iron_NN deficiency_NN could_MD account_VB
          for_IN this_DT enhanced_JJ distensibility_NN ._. It_PRP has_VBZ been_VBN reported_VBN
          that_DT collagen_NN production_NN is_VBZ reduced_VBN in_IN iron_NN deficient_NN
          hearts_NNS [_NN 40_CD ]_NN ,_, but_CC we_PRP are_VBP aware_JJ of_IN no_DT studies_NNS that_WDT have_VBP
          specifically_RB examined_VBN alterations_NNS in_IN collagen_NN production_NN
          in_IN iron_NN deficient_NN arteries_NNS ._. Further_RB research_NN regarding_VBG
          this_DT issue_NN is_VBZ warranted_VBN ._.
        
        
          Experiment_NNP 3_CD
          Figure_NN 7_CD shows_VBZ the_DT heart_NN weight_NN to_TO body_NN weight_NN ratio_NN
          for_IN rats_NNS that_WDT received_VBD a_DT daily_JJ intra-peritoneal_JJ injection_NN
          of_IN either_DT the_DT beta-blocker_NN propanolol_NN or_CC saline_NN for_IN 1_CD
          month_NN ._. This_DT ratio_NN was_VBD significantly_RB greater_JJR in_IN rats_NNS fed_VBD
          the_DT iron_NN deficient_NN diet_NN than_IN controls_NNS (_( *_NN ,_, p_NN =_SYM 0_CD ._. 0002_CD )_) ._.
          Clearly_RB ,_, iron_NN deficient_NN cardiac_JJ hypertrophy_NN is_VBZ not_RB caused_VBN
          by_IN chronic_JJ stimulation_NN of_IN beta-adrenergic_JJ receptors_NNS in_IN
          the_DT heart_NN ._.
          Many_JJ studies_NNS have_VBP shown_VBN that_IN chronic_JJ intravenous_JJ
          infusion_NN of_IN norepinephrine_NN is_VBZ sufficient_JJ to_TO cause_VB
          hypertrophy_NN ,_, and_CC that_IN various_JJ forms_NNS of_IN hypertrophy_NN are_VBP
          linked_VBN to_TO a_DT decrease_NN in_IN either_DT beta-adrenergic_JJ receptor_NN
          density_NN or_CC a_DT decreased_VBD responsiveness_NNS to_TO beta-adrenergic_JJ
          stimulation_NN [_NN 46_CD 48_CD 49_CD 56_CD 57_CD 58_CD 59_CD 60_CD 61_CD 62_CD 63_CD ]_NN ._. Barth_NNP ,_,
          for_IN example_NN ,_, showed_VBD that_DT norepinephrine_NN infusion_NN induced_VBN
          left_VBD ventricular_NN hypertrophy_NN that_WDT could_MD be_VB prevented_VBN by_IN
          an_DT adrenergic-receptor_JJ blocker_NN [_NN 58_CD ]_NN ._. It_PRP has_VBZ been_VBN
          suggested_VBN that_DT ornithine_NN decarboxylase_NN is_VBZ a_DT link_NN between_IN
          beta-adrenoreceptors_JJ and_CC stimulation_NN of_IN tissue_NN growth_NN
          factor_NN ,_, which_WDT results_VBZ in_IN hypertrophy_NN [_NN 64_CD ]_NN ._. However_RB ,_,
          recent_JJ studies_NNS have_VBP focused_VBN on_IN alpha-adrenergic_JJ reception_NN
          as_IN a_DT mediator_NN of_IN cardiac_JJ hypertrophy_NN [_NN 35_CD ]_NN ,_, although_IN
          some_DT question_NN the_DT role_NN of_IN the_DT alpha-adrenergic_JJ receptor_NN
          as_IN a_DT hypertrophic_JJ mediator_NN in_IN vivo_NN [_NN 34_CD ]_NN ._. To_TO date_NN ,_, no_DT
          published_VBN studies_NNS of_IN which_WDT we_PRP are_VBP aware_JJ have_VBP examined_VBN
          alpha-adrenergic_JJ reception_NN and_CC the_DT development_NN of_IN cardiac_JJ
          hypertrophy_NN with_IN iron_NN deficiency_NN ._.
          The_DT literature_NN surrounding_VBG norepinephrine_NN and_CC its_PRP$ role_NN
          in_IN the_DT development_NN of_IN iron_NN deficient_NN hypertrophy_NN
          documents_VBZ the_DT following_JJ facts_NNS :_: 1_LS )_) prolonged_JJ iron_NN
          deficiency_NN causes_NNS cardiac_JJ hypertrophy_NN [_NN 11_CD 12_CD 13_CD 14_CD 15_CD 16_CD
          17_CD 23_CD ]_NN ,_, 2_LS )_) the_DT pool_NN of_IN stored_VBD norepinephrine_NN in_IN the_DT
          heart_NN is_VBZ decreased_VBN with_IN iron_NN deficiency_NN [_NN 17_CD 21_CD ]_NN ,_, 3_LS )_)
          plasma_NN and_CC urine_NN concentrations_NNS of_IN norepinephrine_NN are_VBP
          increased_VBN with_IN iron_NN deficiency_NN [_NN 19_CD 20_CD 21_CD 22_CD 68_CD ]_NN ,_, and_CC
          4_LS )_) chronic_JJ administration_NN of_IN reserpine_NN (_( which_WDT depletes_VBZ
          norepinephrine_NN )_) prevents_VBZ the_DT development_NN of_IN iron_NN
          deficient_NN hypertrophy_NN [_NN 12_CD ]_NN ,_, but_CC not_RB hypertrophy_NN that_IN
          results_NNS from_IN aortic_JJ banding_VBG [_NN 23_CD ]_NN ._. This_DT ,_, combined_VBN with_IN
          other_JJ studies_NNS that_WDT relate_VBP chronic_JJ adrenergic_JJ stimulation_NN
          to_TO hypertrophy_NN ,_, led_VBD Rossi_NNP to_TO the_DT conclusion_NN that_DT iron_NN
          deficiency_NN hypertrophy_NN was_VBD caused_VBN by_IN chronic_JJ sympathetic_JJ
          stimulation_NN ._. However_RB ,_, our_PRP$ finding_VBG that_IN a_DT daily_JJ injection_NN
          of_IN the_DT beta-blocker_NN propanolol_NN does_VBZ not_RB prevent_VB the_DT
          development_NN of_IN iron_NN deficient_NN cardiac_JJ hypertrophy_NN
          suggests_VBZ that_IN beta-adrenergic_JJ sympathetic_JJ stimulation_NN may_MD
          not_RB be_VB a_DT causal_NN agent_NN in_IN the_DT development_NN of_IN hypertrophy_NN ._.
          Future_JJ investigation_NN is_VBZ warranted_VBN into_IN the_DT potential_JJ
          alpha-adrenergic_JJ role_NN in_IN this_DT hypertrophy_NN ._.
        
      
      
        Conclusions_NNP
        The_DT purpose_NN of_IN this_DT study_NN was_VBD to_TO investigate_VB cardiac_JJ and_CC
        vascular_NN responses_NNS associated_VBN with_IN the_DT development_NN of_IN iron_NN
        deficiency_NN ._. In_IN our_PRP$ first_JJ experiment_NN ,_, we_PRP tested_VBD the_DT
        hypothesis_NNS that_IN the_DT iron_NN deficient_NN heart_NN would_MD display_VB an_DT
        altered_VBN response_NN to_TO norepinephrine_NN ,_, the_DT sympathetic_JJ nervous_JJ
        system_NN neurotransmitter_NN ._. In_IN contrast_NN to_TO what_WP has_VBZ been_VBN seen_VBN
        with_IN most_JJS cardiac_JJ disease_NN states_NNS ,_, we_PRP found_VBD that_IN the_DT iron_NN
        deficient_NN heart_NN is_VBZ hyper-sensitive_JJ to_TO norepinephrine_NN ._. This_DT
        suggests_VBZ an_DT adaptive_JJ compensation_NN to_TO the_DT depletion_NN of_IN the_DT
        neurotransmitter_NN stores_NNS in_IN the_DT heart_NN sympathetic_JJ nerve_NN
        terminals_NNS ._. Further_RB ,_, we_PRP found_VBD that_DT contractility_NN was_VBD
        enhanced_VBN ,_, but_CC heart_NN rate_NN was_VBD not_RB ._. This_DT would_MD allow_VB for_IN the_DT
        iron_NN deficient_NN animal_NN to_TO increase_VB cardiac_JJ output_NN through_IN
        enhanced_JJ stroke_NN volume_NN ,_, while_IN maintaining_VBG the_DT amount_NN of_IN
        time_NN available_JJ for_IN cardiomyocyte_NN perfusion_NN ._.
        Our_PRP$ second_JJ experiment_NN was_VBD designed_VBN to_TO investigate_VB
        whether_IN vascular_NN morphology_NN would_MD be_VB altered_VBN with_IN iron_NN
        deficiency_NN ._. Our_PRP$ results_NNS show_VBP an_DT increase_NN in_IN abdominal_NN aorta_NN
        diameter_NN ,_, suggesting_VBG that_IN a_DT flow-dependent_JJ remodeling_NN of_IN
        the_DT arterial_NN wall_NN occurred_VBD ._. Also_RB ,_, distensibility_NN was_VBD
        significantly_RB increased_VBN ,_, which_WDT we_PRP suggest_VBP may_MD be_VB due_JJ to_TO a_DT
        reduction_NN in_IN arterial_NN collagen_NN ._. These_DT morphological_JJ
        adjustments_NNS can_MD be_VB seen_VBN as_IN a_DT positive_JJ adaptation_NN to_TO
        simultaneously_RB reduce_VB afterload_NN on_IN the_DT heart_NN and_CC improve_VB
        blood_NN flow_NN to_TO peripheral_JJ tissues_NNS ._.
        Our_PRP$ final_JJ experiment_NN was_VBD a_DT simple_JJ test_NN to_TO determine_VB if_IN
        the_DT beta-adrenergic_JJ antagonist_NN propanolol_NN would_MD prevent_VB
        hypertrophy_NN ._. The_DT failure_NN of_IN the_DT beta-blocker_NN to_TO prevent_VB
        hypertrophy_NN suggests_VBZ that_IN ,_, if_IN the_DT sympathetic_JJ nervous_JJ
        system_NN is_VBZ a_DT causal_NN agent_NN in_IN the_DT development_NN of_IN this_DT form_NN of_IN
        hypertrophy_NN ,_, the_DT signaling_VBG mechanism_NN is_VBZ not_RB mediated_JJ by_IN the_DT
        beta-adrenergic_JJ receptor_NN ._.
        In_IN summary_NN ,_, much_JJ remains_VBZ to_TO be_VB learned_VBN about_IN this_DT form_NN
        of_IN hypertrophy_NN ._. Further_RB experimentation_NN may_MD serve_VB to_TO
        elucidate_NN not_RB only_RB the_DT pathology_NN of_IN iron_NN deficient_NN cardiac_JJ
        hypertrophy_NN ,_, but_CC other_JJ forms_NNS of_IN this_DT pathology_NN as_RB well_RB ._.
      
      
        Materials_NNS and_CC methods_NNS
        
          Experiment_NNP 1_CD :_: cardiovascular_JJ response_NN to_TO
          norepinephrine_NN
          
            Experimental_NNP procedure_NN
            Rats_NNP were_VBD sedated_JJ by_IN intra-muscular_JJ injection_NN (_( right_NN
            hamstring_VB )_) of_IN 65_CD mg_NN ·_NN kg_NN -_: 1_CD body_NN mass_NN ketamine_NN
            hydrochloride_NN ._. Three_CD minutes_NNS later_RB ,_, they_PRP were_VBD
            anesthetized_JJ with_IN 6_CD ._. 5_CD mg_NN ·_NN kg_NN -_: 1_CD body_NN mass_NN xylazine_NN ._.
            Adequate_NNP anesthesia_NN was_VBD demonstrated_VBN by_IN little_JJ or_CC no_DT
            withdrawal_NN reflex_JJ to_TO a_DT toe_NN pinch_NN ._. Once_RB anesthetized_JJ ,_,
            one_CD PE-_NNP 50_CD (_( Becton-_NNP Dickinson_NNP )_) catheter_NN filled_VBN with_IN
            heparinized_JJ saline_NN solution_NN (_( 131_CD ._. 9_CD mM_NN NaCl_NNP ,_, 4_CD ._. 7_CD mM_NN KCl_NNP ,_,
            2_CD ._. 0_CD mM_NN CaCl_NNP 
            2_CD ,_, 1_CD ._. 17_CD mM_NN MgSO_NNP 
            4_CD ,_, 17_CD ._. 4_LS mM_NN NaHCO_NNP 
            3_CD ,_, 50_CD IU_NNP heparin_NN sodium_NN )_) was_VBD
            surgically_RB implanted_VBN into_IN the_DT right_JJ carotid_NN artery_NN ,_, and_CC
            another_DT into_IN the_DT left_NN jugular_NN vein_NN ._.
            Following_VBG catheterization_NN and_CC closure_NN of_IN the_DT
            incision_NN ,_, the_DT carotid_NN catheter_NN was_VBD connected_VBN to_TO a_DT
            pressure_NN transducer_NN (_( Cobe_NNP Model_NNP CDX_NNP III_NNP )_) and_CC analog_NN to_TO
            digital_JJ conversion_NN system_NN (_( ETH-_NNP 250_CD bridge_NN /_NN bio-amplifier_JJ
            used_VBN in_IN bridge_NN mode_NN with_IN an_DT input_NN gain_NN of_IN 100_CD ×_NN and_CC a_DT 50_CD
            Hz_NNP filter_NN ,_, C_NNP ._. B_NNP ._. Sciences_NNPS ,_, Inc_NNP ._. and_CC MacLab_NNP /_NN 4_CD E_NNP analog_NN to_TO
            digital_JJ converter_NN ,_, A_DT ._. D_NNP ._. Instruments_NNP ,_, Inc_NNP ._. )_) ._. The_DT
            converter_NN was_VBD connected_VBN via_IN SCSI_NNP interface_NN to_TO an_DT
            accelerated_VBD Power_NNP Mac_NNP 6100_CD /_NN 66_CD computer_NN (_( Apple_NNP Computer_NNP ,_,
            Inc_NNP ._. ,_, Cupertino_NNP ,_, CA_NNP )_) ;_: Chart_NNP software_NN (_( Version_NNP 3_CD ._. 4_CD ._. 2_LS ,_,
            sampling_VBG every_DT 0_CD ._. 01_CD s_VBZ and_CC set_VBN to_TO accept_VB a_DT maximum_NN input_NN
            of_IN 1_CD V_NNP ,_, A_DT ._. D_NNP ._. Instruments_NNP ,_, Inc_NNP ._. )_) was_VBD used_VBN to_TO visualize_VB
            the_DT output_NN ._. The_DT pressure_NN transducer_NN system_NN was_VBD
            calibrated_VBN by_IN mercury_NN manometer_NN at_IN the_DT beginning_NN of_IN
            each_DT experiment_NN ,_, and_CC was_VBD found_VBN to_TO be_VB linear_JJ and_CC
            consistent_JJ throughout_IN the_DT range_NN of_IN pressures_NNS
            measured_VBN ._.
            One_CD hundred_CD microliters_NNS of_IN saline_NN solution_NN was_VBD
            infused_VBN into_IN the_DT jugular_NN vein_NN catheter_NN ,_, and_CC the_DT
            cardiovascular_JJ response_NN was_VBD recorded_VBN via_IN the_DT carotid_NN
            pressure_NN transducer_NN until_IN pressure_NN stabilized_VBN near_IN its_PRP$
            baseline_NN value_NN ._. This_DT procedure_NN was_VBD repeated_VBN using_VBG 100_CD
            μL_NN of_IN 1_CD ._. 52_CD mM_NN norepinephrine_NN (_( in_IN saline_NN solution_NN )_) ,_, and_CC
            the_DT arterial_NN trace_VB recorded_VBN ._.
          
          
            Data_NNP Treatment_NNP and_CC Statistical_NNP Analysis_NNP
            Cardiovascular_NNP variables_NNS were_VBD analyzed_VBN immediately_RB
            prior_RB to_TO infusion_NN (_( pre-infusion_JJ )_) and_CC at_IN the_DT maximal_NN
            pressor_NN response_NN (_( peak_NN response_NN )_) ,_, 20_CD s_VBZ after_IN jugular_NN
            infusion_NN ._. Chart_NNP software_NN was_VBD used_VBN to_TO determine_VB minimal_JJ
            (_( diastolic_JJ )_) and_CC maximal_NN (_( systolic_JJ )_) pressures_NNS and_CC heart_NN
            rate_NN ._. Contractility_NNP (_( dP_NN •_NN dt_NN -_: 1_LS )_) was_VBD measured_VBN as_IN the_DT
            average_JJ slope_NN between_IN each_DT pair_NN of_IN data_NNS points_NNS within_IN
            the_DT systolic_JJ pulse_NN ._. Pulse_NNP pressure_NN was_VBD calculated_VBN as_IN
            the_DT difference_NN between_IN systolic_JJ and_CC diastolic_JJ
            pressures_NNS ._.
            Analysis_NNP of_IN Variance_NNP was_VBD performed_VBN using_VBG StatView_NNP
            software_NN (_( Version_NNP 5_CD ._. 0_CD ._. 1_LS ,_, SAS_NNP Institute_NNP ,_, Cary_NNP ,_, NC_NNP )_) ,_, to_TO
            determine_VB diet_NN (_( iron_NN deficient_NN vs_NNS ._. control_NN )_) and_CC
            duration_NN (_( 1_CD week_NN vs_NNS ._. 1_CD month_NN )_) effects_NNS ._. Paired_NNP t-tests_JJ
            were_VBD employed_VBN to_TO determine_VB significant_JJ changes_NNS from_IN
            pre-infusion_JJ to_TO peak_VB response_NN ._. Dependent_NNP variables_NNS were_VBD
            heart_NN rate_NN ,_, contractility_NN ,_, systolic_JJ pressure_NN ,_, and_CC
            diastolic_JJ pressure_NN ._. Probabilities_NNP below_IN 0_CD ._. 05_CD were_VBD
            accepted_VBN as_IN significant_JJ for_IN all_DT statistical_JJ procedures_NNS
            throughout_IN all_DT experiments_NNS in_IN this_DT study_NN ._.
          
        
        
          Experiment_NNP 2_CD :_: remodeling_NN of_IN abdominal_NN aorta_NN
          
            Experimental_NNP Procedures_NNP
            After_IN experiment_NN 1_CD ,_, the_DT rats_NNS were_VBD decapitated_JJ ._. The_DT
            abdominal_NN aorta_NN was_VBD carefully_RB exposed_VBN ,_, and_CC two_CD
            catheters_NNS were_VBD surgically_RB implanted_VBN ._. The_DT first_JJ was_VBD
            inserted_VBN just_RB caudal_NN to_TO the_DT superior_JJ mesenteric_JJ artery_NN ,_,
            and_CC the_DT other_JJ just_RB cranial_NN to_TO the_DT inferior_JJ mesenteric_JJ
            artery_NN ._. The_DT superior_JJ catheter_NN was_VBD used_VBN for_IN stepwise_NN
            saline_NN infusions_NNS at_IN a_DT range_NN of_IN pressures_NNS from_IN 0_CD -_: 120_CD
            mmHg_NN ._. Exact_JJ pressures_NNS were_VBD measured_VBN via_IN a_DT pressure_NN
            transducer_NN attached_VBN to_TO the_DT inferior_JJ catheter_NN ._. Digital_NN
            images_NNS of_IN the_DT abdominal_NN aorta_NN were_VBD taken_VBN at_IN each_DT
            pressure_NN with_IN a_DT Kodak_NNP DC_NNP 120_CD digital_JJ camera_NN coupled_VBN to_TO a_DT
            dissecting_VBG microscope_NN (_( Leica_NNP MZ_NNP 6_CD )_) ._. The_DT external_JJ
            diameter_NN of_IN the_DT abdominal_NN aorta_NN was_VBD measured_VBN using_VBG NIH_NNP
            image_NN software_NN (_( Version_NNP 1_CD ._. 62_CD ,_, National_NNP Institutes_NNPS of_IN
            Health_NNP ,_, Bethesda_NNP ,_, MD_NNP )_) on_IN an_DT accelerated_VBN Power_NNP Mac_NNP
            7500_CD /_NN 100_CD (_( Apple_NNP Computer_NNP ,_, Cupertino_NNP ,_, Ca_MD )_) ._. The_DT system_NN
            was_VBD calibrated_VBN by_IN using_VBG the_DT digital_JJ image_NN of_IN a_DT ruler_NN at_IN
            the_DT same_JJ magnification_NN ._.
          
          
            Data_NNP Treatment_NNP and_CC Statistical_NNP Analysis_NNP :_:
            Regression_NNP analysis_NN was_VBD performed_VBN using_VBG aorta_NN
            external_JJ diameter_NN and_CC inflation_NN pressure_NN as_IN dependent_JJ
            and_CC independent_JJ variables_NNS ,_, respectively_RB ._. Distensibility_NNP
            was_VBD estimated_VBN as_IN the_DT slope_NN of_IN the_DT regression_NN line_NN for_IN
            each_DT individual_JJ animal_NN ._. The_DT external_JJ diameter_NN of_IN the_DT
            abdominal_NN aorta_NN at_IN 100_CD mmHg_NN pressure_NN was_VBD also_RB estimated_VBN
            from_IN the_DT individual_JJ regression_NN equations_NNS ._. Analysis_NNP of_IN
            Variance_NNP was_VBD then_RB performed_VBN on_IN distensibility_NN and_CC 100_CD
            mmHg_NN external_JJ diameter_NN ._.
          
        
        
          Experiment_NNP 3_CD :_: propanolol_NN effects_NNS on_IN heart_NN
          morphology_NN
          
            Experimental_NNP procedures_NNS
            Ten_CD rats_NNS (_( 5_CD iron_NN deficient_NN and_CC 5_CD control_NN )_) were_VBD given_VBN
            a_DT daily_JJ intra-peritoneal_JJ injection_NN of_IN either_DT propanolol_NN
            (_( 50_CD mg_NN •_NN kg_NN -_: 1_CD body_NN mass_NN per_IN day_NN )_) or_CC saline_NN solution_NN ._.
            After_IN 1_CD month_NN ,_, the_DT rats_NNS were_VBD sacrificed_JJ by_IN decapitation_NN
            and_CC the_DT hearts_NNS were_VBD carefully_RB extracted_VBN and_CC
            weighed_VBN ._.
          
          
            Data_NNP treatment_NN and_CC statistical_JJ analysis_NN
            The_DT heart_NN mass_NN to_TO body_NN mass_NN ratio_NN was_VBD calculated_VBN ,_,
            and_CC Analysis_NNP of_IN Variance_NNP was_VBD performed_VBN as_IN above_IN ._.
          
        
      
    
  
